Every one of those 1 sits in a single category, pharma. American Vanguard is most often covered alongside Eric Wintemute, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about American Vanguard
Every one of those 1 sits in a single category, pharma. American Vanguard is most often covered alongside Eric Wintemute, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. They are less corroborated than the beat average, carrying 3 original sources each against 3.3 for the same window. We currently track 1 Biotech story that mention American Vanguard, all published on March 17, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering American Vanguard. Shared-story counts are live from our verified record — not editorial picks.
American Vanguard (NYSE: AVD) reported its full-year 2025 financial results, highlighting a return to growth following a period of strategic restructuring and inventory destocking in the global agricultural sector. The company emphasized the expansion of its 'Green Solutions' biological portfolio and the successful implementation of its business transformation initiative.
American Vanguard is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.